Search results
Results from the WOW.Com Content Network
VAMP regimen or VAMP chemotherapy is a four-drug combination chemotherapy regimen, used today in the treatment of Hodgkin lymphoma. [1] [2] It was one of the earliest combination chemotherapy regimens, originally developed as a treatment for childhood leukemia by a group of researchers at the National Cancer Institute led by Emil Frei and Emil Freireich.
MOPP was the first combination chemotherapy brought in that achieved a high success rate. It was developed at the National Cancer Institute in the 1960s by a team that included Vincent DeVita, Jr. Although no longer the most effective combination, MOPP is still used after relapse or where the patient has certain allergies or lung or heart ...
In order to develop more effective first-line chemotherapy regimen for aggressive lymphomas, some researchers tried to add toposide to the standard [R]-CHOP regimen. [7] There were also attempts to further improve the efficacy of the [R]-CHOEP regimen with escalating the chemotherapy doses. This mode was called [R]-High-CHOEP. However, it did ...
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...
Upload file; Languages. ... Download as PDF; Printable version; Help. Pages in category "Chemotherapy regimens used in lymphoma" The following 22 pages are in this ...
Hodgkin lymphoma typically is treated with radiotherapy alone, as long as it is localized. [59] Advanced Hodgkin disease requires systemic chemotherapy, sometimes combined with radiotherapy. [60] Chemotherapy used includes the ABVD regimen, which is commonly used in the United States.
It was established as Clinical Lymphoma in 2000, renamed to Clinical Lymphoma & Myeloma in 2005 and obtained its current name in 2010. The journal covers research on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia, and related disorders, including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias.
ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs: It consists of concurrent treatment with the chemotherapy drugs: